Savara Inc. (SVRA) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is MOLBREEVI (molgramostim inhalation solution), an investigational inhaled biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company has no product revenue to date and operates as a single segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(37.3) million | $(26.6) million |
| Net Loss Per Share (Basic/Diluted) | $(0.15) | $(0.12) |
| Operating Expenses | $39.0 million | $28.4 million |
| Cash & Cash Equivalents | $38.8 million | $19.6 million |
| Short-term Investments | $164.0 million | $202.5 million |
| Total Liquidity | $202.8 million | $222.1 million |
| Long-term Debt | $30.1 million | $29.9 million |
| Cash Used in Operating Activities | $(33.0) million | $(27.2) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $10.6 million (40%) year-over-year, driven by higher operating expenses.
- R&D Expenses: Increased by $4.2 million (22%) to $23.4 million. Drivers included $2.5 million in chemistry, manufacturing, and controls (CMC) activities and $3.0 million in higher personnel costs (primarily stock-based compensation).
- G&A Expenses: Increased by $6.3 million (68%) to $15.6 million, primarily due to $6.0 million in higher personnel costs related to stock-based compensation.
- Stock-Based Compensation: Total expense rose significantly to $10.7 million from $3.0 million in the prior year.
- Investment Portfolio: Short-term investments decreased by approximately $38.5 million due to maturities and sales, though cash equivalents increased.
Outlook, Risks, and Management Commentary
- Regulatory Status: The FDA extended the review period for the MOLBREEVI Biologics License Application (BLA), setting a new Prescription Drug User Fee Act (PDUFA) date of November 22, 2026. The European Medicines Agency (EMA) validated the marketing authorization application (MAA) in March 2026, with a decision expected in Q1 2027. The UK MHRA also validated the MAA with an accelerated review.
- Liquidity & Funding: Management states the company has sufficient capital to fund planned activities but may need to raise additional capital for commercialization. The company has a debt facility with Hercules Capital allowing for up to $105 million in term loans, with $30 million currently drawn. Additional tranches are contingent on FDA approval.
- Royalty Agreement: In October 2025, the company entered a royalty purchase and sale agreement with RTW Investments, LP, potentially providing $75.0 million upon FDA approval by March 31, 2027, in exchange for a tiered royalty on U.S. net sales.
- Risks: Key risks include the uncertainty of regulatory approval, the need for additional financing, and the potential for the product to fail to achieve market acceptance. The company has an accumulated deficit of $645.4 million.
Investor Verification Checklist
- Regulatory Timeline: Verify the implications of the FDA's PDUFA date extension to November 2026 on cash burn and funding needs.
- Debt Covenants: Review the specific financial covenants in the Hercules Loan Agreement, particularly the "Cash Requirement" and "Conditional Minimum Revenue Covenant" extended to 2027.
- Royalty Agreement Terms: Confirm the specific conditions for the $75 million payment from RTW Investments and the impact of the embedded derivative liability ($0.4 million recorded).
- Stock-Based Compensation: Assess the sustainability of the sharp increase in stock-based compensation ($10.7M in Q1) and its impact on future dilution.
- Manufacturing Commitments: Review the $46.3 million estimated fees for FujiFilm Diosynth and other manufacturing obligations to ensure liquidity coverage.